Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 799-801 |
| Number of pages | 3 |
| Journal | The Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 4 |
| Issue number | 5 |
| Early online date | 30 Aug 2016 |
| DOIs | |
| Publication status | Published - Sep 2016 |
Fingerprint
Cite this
Respiratory Medication Adherence : Toward a Common Language and a Shared Vision. / Van Ganse, Eric; Price, David.
In: The Journal of Allergy and Clinical Immunology: In Practice, Vol. 4, No. 5, 09.2016, p. 799-801.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Respiratory Medication Adherence
T2 - Toward a Common Language and a Shared Vision
AU - Van Ganse, Eric
AU - Price, David
N1 - Part of this work, conducted by E. Van Ganse, has been performed in the context of the ASTRO-LAB project, which received funding from the European Community's 7th Framework (FP7/2007-2013) under grant agreement no. 282593. Teva supported the meeting costs at which the concepts in this paper were discussed by the co-authors and the open access publication fee for this article. The authors had full editorial control over the ideas presented.
PY - 2016/9
Y1 - 2016/9
N2 - The World Health Organization highlights the importance of optimizing chronic respiratory disease (CRD) medication adherence with a view to improving clinical outcomes and alleviating ever-increasing pressures on the world's health care resources.1 and 2 The Global Initiative for Asthma also advocates for optimized adherence, recommending that asthma symptoms and risk be optimized on the lowest dose of therapy appropriate and that high-cost add-on therapies only be considered in patients with severe disease who have persistent symptoms and/or exacerbations despite optimized treatment with high-dose controller medications and treatment of modifiable risk factors.2 This requirement for optimized therapy as a prerequisite to asthma treatment escalations is of increasing relevance as evermore high-cost biological therapies with narrow therapeutic margins are expected to be licensed for CRD. Use of such novel therapies must be targeted at patients with true unmet need to maximize their cost-effectiveness.
AB - The World Health Organization highlights the importance of optimizing chronic respiratory disease (CRD) medication adherence with a view to improving clinical outcomes and alleviating ever-increasing pressures on the world's health care resources.1 and 2 The Global Initiative for Asthma also advocates for optimized adherence, recommending that asthma symptoms and risk be optimized on the lowest dose of therapy appropriate and that high-cost add-on therapies only be considered in patients with severe disease who have persistent symptoms and/or exacerbations despite optimized treatment with high-dose controller medications and treatment of modifiable risk factors.2 This requirement for optimized therapy as a prerequisite to asthma treatment escalations is of increasing relevance as evermore high-cost biological therapies with narrow therapeutic margins are expected to be licensed for CRD. Use of such novel therapies must be targeted at patients with true unmet need to maximize their cost-effectiveness.
U2 - 10.1016/j.jaip.2016.04.006
DO - 10.1016/j.jaip.2016.04.006
M3 - Article
VL - 4
SP - 799
EP - 801
JO - The Journal of Allergy and Clinical Immunology: In Practice
JF - The Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
IS - 5
ER -